Difference between revisions of "Tumor rejection antigen-1"
m |
m |
||
| Line 1: | Line 1: | ||
{| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | {| class="toccolours" border="1" style="float: left; clear: right; margin: 0 0 1em 1em; border-collapse: collapse;" | ||
| − | ! | + | ! {infobox header}| '''{{PAGENAME}}''' |
|- | |- | ||
| Substrate peptide name | | Substrate peptide name | ||
| Line 45: | Line 45: | ||
| | | | ||
|- | |- | ||
| − | | | + | | {infobox header} | |
|- | |- | ||
|} | |} | ||
[[Category:Tissue transglutaminase|*]] | [[Category:Tissue transglutaminase|*]] | ||
Latest revision as of 11:59, 10 March 2015
| Tumor rejection antigen-1 | |
|---|---|
| Substrate peptide name | Tumor rejection antigen-1 |
| Synonyms | Endoplasmin precursor
GRP94 |
| Determination type | In situ/In vitro |
| Source | Homo sapiens |
| Subcellular localization | Endoplasmic reticulum lumen |
| Swissprot ID | P14625 |
| Reactive glutamines | Not determined yet |
| Reactive lysines | Not determined yet |
| Substrate sequence | |
| Structure | No available crystal structure |
| Surface accessibility | |
| Disorder prediction | IUPred |
| Reference | PMID:12799366 |
| Notes | |
